Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate for PBC With Inadequate Response to UDCA
NCT02823366Phase 3Recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Jan 2016
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fenofibrate in primary biliary cholangitis (PBC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Rate of patients with complete biochemical response at 24 weeks. Started Jan 2016; status: recruiting.
02
Drugs
fenofibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02823366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823366.